Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

Inclusion Criteria: * Women between 20-40 years of age with regular monthly menses * If over age 35 then must not use tobacco * Negative pregnancy test * No known allergy to raltegravir * No known history of phenylketonuria * Undetectable HIV viral load * No active liver disease as determined by medical history and normal AST and ALT * No history of hepatic adenomas, carcinomas or benign liver tumors * Ho history of thrombophlebitis of thromboembolic disease * No history of deep vein thrombosis * No history of cerebral vascular or coronary artery disease * No known or suspected carcinoma of the breast * No undiagnosed abnormal genital bleeding * Not taking concomitant CYP 450 inducing medications such as anti-seizure medications * No use of oral contraceptives, depot-medroxyprogesterone acetate, contraceptive ring or patch within two months of screening * No cholestatic jaundice of pregnancy or jaundice with prior contraceptive pill use * Has used raltegravir prior to screening * Has no history of malignancy of the genital tract (e.g. cervical cancer, ovarian cancer, endometrial cancer) * Must not have had an abnormal pap test defined without resolution in the last 18 months.